Phenobarbital for the management of severe acute alcohol withdrawal (the PHENOMANAL trial): a pilot randomized controlled trial.

ABSTRACT:

Background

Benzodiazepines are considered first-line treatment for patients experiencing severe acute alcohol withdrawal syndrome (sAAWS). Although several medications have been evaluated as potential adjuvant treatments for sAAWS, barbiturates show particular promise.

Objective

In the PHENOMANAL trial, we will assess the feasibility of conducting an allocation-concealed, quadruple-blinded, randomized controlled trial (RCT) comparing symptom-triggered benzodiazepine therapy with either a single dose of adjuvant intravenous (IV) phenobarbital (7.5 mg/kg of ideal body weight) or a single dose of matching IV placebo for patients with sAAWS.

Methods

We will recruit adult patients from the Emergency Department, Intensive Care Unit, or hospital wards with a Clinical Institu

SUBMITTER: Filewod N 

PROVIDER: S-EPMC8783453 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature